AIM: To evaluate the efficacy and safety of intravitreous injection of Conbercept for macular edema secondary to macular branch retinal vein occlusion(MBRVO).

METHODS: Clinical records of 19 patients(19 eyes)who were diagnosed MBRVO with macular edema(ME)in our hospital, from July 2015 to September 2016 were retrospectively analysed. All patients were treated with an intravitreal dose of 0.5mg or 0.05mL conbercept ophthalmic injection by the 3+ pro re nata(PRN)project. All patients were evaluated by best corrected visual acuity(BCVA), central retinal thickness(CRT), the number of the injection, and the complications.

RESULTS: During the 1, 2, 3 and 6mo after treatment the mean BCVA all improved significantly(P<0.01), and the mean CRT reduced statistical significantly(P<0.01); 3 eyes had refractory ME, and micro-aneurysm leakage were identified by FFA, and the ME was suppressed effectively after local laser photocoagulation. No complications, such as secondary vitreous haemorrhage, retinal detachment, persistent high intraocular pressure and endophthalmitis were observed during subsequent follow-up.

CONCLUSION: Intravitreous injection of conbercept for macular edema secondary to MBRVO may reduce macular edema and improve visual acuity effectively and safely in the short term.